Clinical trials of PARPi showed anti-cancer efficacy with the approval for Olaparib and talazoparib monotherapies for locally advanced/metastatic deleterious/suspected deleterious germline BRCAmut, Human Epidermal growth factor Receptor (HER2)-negative breast cancers [10,11]. The gene discussed is ERBB2; the disease is breast cancer.